What happened with CELU today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Celularity turns donated placental tissue into ready-to-use materials for covering or repairing soft tissue. Most revenue comes from its biomaterials business, led by Biovance 3L and Rebound. Healthcare providers and distributors buy these products directly or through its distribution network. It has also granted NexGel an exclusive license to develop and commercialize certain products, with upfront consideration, conditional milestone payments and royalties on certain development-stage products. Purchases depend partly on clarity about insurance reimbursement.
Through LifebankUSA, expectant parents pay Celularity to collect, process and freeze umbilical-cord blood and placental cells and tissue, then pay annual storage fees for potential future use. Other companies also pay it for contract manufacturing and development services involving biomaterials and cell therapies.
Celularity separately develops treatments using donated placental cells that are intended to be stored and used across patients. These candidates remain unproven and need regulatory approval before commercial sale. Manufacturing depends on suitable donated placentas, while rights to certain technologies depend on a license from Celeniv.
Its marketed tissue products have no specific FDA approval: Celularity believes they qualify for a human-tissue regulatory route that limits processing and intended uses. Wound healing does not qualify as an allowed same-function use under that route; broader claims could require approval or force sales to stop. The company also needs outside capital because operating cash generation is insufficient to sustain operations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Celularity’s results hinge on wound-care reimbursement and its NexGel licensing arrangement, while certain technologies also depend on retaining license rights from Celeniv.
MiMedx Group, Inc and Celularity compete for wound-care and surgical-repair purchases with grafts made from donated placental tissue. Watch MiMedx’s U.S. wound-care sales for clues to provider demand, as reimbursement uncertainty has led Celularity’s providers and distributors to defer or limit orders.
Organogenesis Holdings Inc. and Celularity both sell wound-repair products to providers whose purchases depend on insurance coverage and reimbursement. Watch coverage for Organogenesis’s PuraPly and NuShield, which most private payers cover only narrowly, alongside the reimbursement uncertainty weighing on Celularity’s Biovance 3L and Rebound orders.
NexGel, Inc holds exclusive rights to develop and sell certain Celularity wound-care and degenerative-disease products, linking those sales to payments and potential royalties for Celularity. Watch net sales: the amended first $2.5 million milestone is due at $25 million in net sales, or 15 months after commencement if net sales have reached at least $15 million by then.
Fate Therapeutics, Inc. competes with Celularity in cancer treatments using frozen, ready-to-use natural killer (NK) cells, but makes its cells from reprogrammed stem cells rather than placental stem cells. Its ability to mass-produce and store uniform NK-cell candidates provides a manufacturing comparison for Celularity’s CYNK platform.
Artiva Biotherapeutics, Inc. and Celularity compete in ready-to-use NK-cell therapies made from donor cells, so clinical results and the ability to scale production matter to both. Watch Artiva’s AlloNK results in autoimmune disease and its batch consistency; it had no product-sales revenue through December 31, 2025.
Nkarta, Inc. competes with Celularity’s engineered placental NK-cell platform using healthy-donor NK cells modified to recognize treatment targets, known as CAR-NK cells. Its lead candidate NKX019 now targets autoimmune diseases, so those clinical results are not a direct test of Celularity’s cancer-treatment approach.
Century Therapeutics, Inc. competes with Celularity’s placental NK-cell platform using NK cells made from reprogrammed stem cells, although its current priorities lean toward autoimmune disease and diabetes. Watch CNTY-101 in the CARAMEL autoimmune-disease trial as a comparison for NK-cell development, rather than a direct readout on Celularity’s cancer therapies.
Senti Biosciences Holdings, Inc. and Celularity both develop donor-derived NK-cell therapies, making advances in engineered NK-cell treatment relevant to Celularity’s platform. Watch trial updates from Senti’s gene-circuit research platform, rather than treating its development business as a comparison for Celularity’s wound-care sales.
MiMedx Group, Inc earningsMDXG
MiMedx’s report will show whether its U.S. wound-care sales hold up; both MiMedx and Celularity sell placental-tissue grafts to healthcare providers.
Look at MiMedx’s U.S. wound-care sales and what the company says about provider purchasing. Sales holding up would suggest providers are still buying comparable grafts despite reimbursement uncertainty, so Celularity’s order pressure may be more specific to its products or coverage. Weaker sales would suggest broader provider caution may also be weighing on orders for Celularity’s Biovance 3L and Rebound.
NexGel, Inc earningsNXGL
NexGel’s report will show how sales of Celularity-licensed wound-care products are progressing, which affects whether Celularity receives a later milestone payment.
Focus on net sales of the licensed products. Under the amended agreement, the first $2.5 million milestone is due when net sales reach $25 million; it is also due at 15 months after commencement if net sales have reached at least $15 million by then. Sales moving toward either threshold would show commercial progress and could bring Celularity that payment; weaker sales would leave this later revenue uncertain.
Fate Therapeutics, Inc. earningsFATE
Fate Therapeutics’ report can show whether it can consistently make and store ready-to-use NK-cell therapies, offering a manufacturing comparison for Celularity’s CYNK platform.
Watch for updates on production consistency and frozen storage of Fate Therapeutics’ NK-cell candidates. Evidence that it can reliably make and store ready-to-use candidates would show that a competing platform may clear a manufacturing hurdle, but its cells come from reprogrammed stem cells and that would not prove Celularity can do the same with placental-derived CYNK. Continued manufacturing problems would underline the scale-up challenge for ready-to-use NK therapies; Celularity’s own performance would still have to be judged from its reports.
Celularity Inc. earningsThis company
Celularity’s report will show whether sales of wound-care products such as Biovance 3L and Rebound can provide steadier revenue and ease its need for outside funding.
Read Product Sales and License, royalty and other revenue alongside cash used in operations. Direct biomaterial sales go in Product Sales; sales through distribution partners go in License, royalty and other, which can also include licensing income. Steadier or rising product sales with less cash used in operations would show the commercial business is helping ease funding pressure. Weakening product sales with continued cash outflow would show revenue is not enough to remove the need for outside financing.
